CML drugs may secretly alter metabolism – study to investigate
NCT ID NCT07413263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 75 people with chronic myeloid leukemia who are taking tyrosine kinase inhibitors (imatinib or nilotinib). Researchers want to see if these drugs change blood sugar (HbA1c) and cholesterol levels. The goal is to understand side effects better, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tyrosine kinase inhibitors (imatinib and nilotinib)
- What this could lead to
- If successful, this could help doctors better manage the side effects of CML drugs on metabolism.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to any new therapies or changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can donor immune cells tame stem cell transplant risks?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Could bone marrow from deceased donors cure blood cancers?
- New hope for young adults with CML: asciminib under Real-World scrutiny